Trinity Biotech Plc
Officers & Directors
1. Kevin Tansley - CEO & Director Kevin Tansley joined Trinity Biotech Plc in 2018 as the CEO. Prior to this, he served as the President and CEO of ZetrOZ Systems LLC. Kevin brings more than 25 years of experience in the healthcare industry. 2. Ronan O'Caoimh - Chairman of the Board & Independent Director Ronan O'Caoimh served as the CEO of Trinity Biotech Plc from 1992 until 2018. He now serves as the Chairman of the Board. Ronan has over 35 years of experience in the medical diagnostics industry. 3. Richard A. Lerner - Independent Director Richard A. Lerner is a professor at The Scripps Research Institute and an independent director of Trinity Biotech Plc. He has served on numerous biotech company boards and has been a leader in antibody therapeutics research. 4. Brendan Farrell - Independent Director Brendan Farrell is an independent director of Trinity Biotech Plc. He was the founder and CEO of Eirgen Pharma, which was acquired by OPKO Health in 2015. 5. John B. Morrison - Independent Director John B. Morrison, PhD, is an independent director of Trinity Biotech Plc. He currently serves as the CEO of the Institute for Systems Biology and has been involved in a number of biotech and healthcare ventures throughout his career.
Trinity Biotech Plc currently has 380 employees.
News about Trinity Biotech Plc Key Personnel |
Trinity Biotech Plc, a leading healthcare company, has recently announced that its New York-based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjogren s Syndrome Test Panel. This strategic move aims to enhance market access and increase profitability for the company. However, it comes amidst Trinity Biotech s recorded net loss and a declining return on investment (ROI) during the fourth quarter of 2022.
Facts:
1. Trinity Biotech s New York-based reference laboratory, Immco Diagnostics, has applied for a PLA code for its Early Sjogren s Syndrome Test Panel.
2. The application is expected to facilitate an optimized mar...
|
Trinity Biotech, a leading global provider of diagnostic solutions, has recently made significant changes to its management team. The company announced that John Gillard has been appointed as the new Chief Executive Officer (CEO), bringing with him a wealth of experience and expertise. In addition, Des Fitzgerald has been named as the Interim Chief Financial Officer (CFO), ensuring smooth financial management during this transition period.
The appointment of John Gillard as the CEO marks an exciting new chapter for Trinity Biotech. With a proven track record of success in the healthcare industry, Gillard brings a fresh perspective and strategic vision to the company. His leadership skills and d...
|
|
